Created in partnership with individuals living with HS and their dermatologists, this new campaign features stories of those living with HS, informational videos, and interactive tools and resources for those seeking management options, daily care, and information about HS.
Tag Archive for: hidradenitis suppurativa
Over the weekend, at the American Academy of Dermatology annual meeting, Novartis revealed early Phase IIb data from 66 patients who had been treated with either 25 mg or 100 mg of remibrutinib, which was dosed twice-daily.
The FDA on Friday approved Alvotech and Teva’s Simlandi (adalimumab-ryvk), a biosimilar to AbbVie’s blockbuster antibody therapy Humira (adalimumab), ending a long and difficult regulatory road for the partners.
The Swiss pharma has set up its challenge to AbbVie’s blockbuster immunosuppressive drug Humira with a label expansion for Cosentyx in hidradenitis suppurativa, a painful long-term skin condition.
Following a $540 million IPO in May, Acelyrin’s lead candidate izokibep failed to meet the primary endpoint in a Phase IIb/III study of patients with the chronic inflammatory skin condition.
Due to safety concerns, Aristea Therapeutics announced Friday it is discontinuing the development of its Phase II lead program RIST4721. As a result, the San Diego-based biotech is also dissolving its business.
Novartis said its anti-inflammatory drug Cosentyx eased the symptoms of a painful, lump-forming skin condition in two late-stage trials, putting the approved treatment on track to further shore up sales growth at the Swiss drugmaker.
